This is a Phase 1/2, multicenter, open-label, dose-escalation study that will determine the MTD and RP2D of L-Annamycin in combination with cytarabine for the treatment of subjects with AML.

开始日期2022-09-29

申办/合作机构

Moleculin Biotech, Inc.

NCT03388749 / Completed临床1/2期

Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Induction Therapy

This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after induction therapy

开始日期2018-12-17

申办/合作机构

Moleculin Biotech, Inc.

NCT03315039 / Completed临床1/2期

Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Standard Induction Therapy

开始日期2018-03-28

申办/合作机构

Moleculin Biotech, Inc.

100 项与安纳霉素相关的临床结果

登录后查看更多信息

100 项与安纳霉素相关的转化医学

登录后查看更多信息

100 项与安纳霉素相关的专利（医药）

登录后查看更多信息

项与安纳霉素相关的文献（医药）

2023-02-24·European journal of cancer (Oxford, England : 1990)

Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?

Review

作者: Dempke, Wolfram C. M. ; Zielinski, Rafal ; Winkler, Christina ; Silberman, Sandra ; Reuther, Susanne ; Priebe, Waldemar

Anthracyclines have contributed significantly to remarkable improvements in overall survival and are regarded as the most effective cytostatic drug for cancer treatment in various malignancies. However, anthracyclines are a significant cause of acute and chronic cardiotoxicity in cancer patients, and long-term cardiotoxicity can lead to death in about one-third of patients. Several molecular pathways have been implicated in the development of anthracycline-induced cardiotoxicity, although the underlying mechanisms of some molecular pathways are not fully elucidated. It is now generally believed that anthracycline-induced reactive oxygen species (resulting from intracellular metabolism of anthracyclines) and drug-induced inhibition of topoisomerase II beta are the key mechanisms responsible for the cardiotoxicity. To prevent cardiotoxicity, several strategies are being followed: (i) angiotensin-converting enzyme inhibitors, sartans, beta-blockers, aldosterone antagonists, and statins; (ii) iron chelators; and (iii) by development of new anthracycline derivatives with little or no cardiotoxicity. This review will discuss clinically evaluated doxorubicin analogues that were developed as potentially non-cardiotoxic anticancer agents and include recent development of a novel liposomal anthracycline (L-Annamycin) for the treatment of soft-tissue sarcoma metastatic to the lung and acute myelogenous leukaemia.

2018-01-01·Forensic toxicology3区 · 医学

Use of hepatocytes isolated from a liver-humanized mouse for studies on the metabolism of drugs: application to the metabolism of fentanyl and acetylfentanyl.

3区 · 医学

Article

作者: Tatsuyuki Kanamori ; Yuko Togawa-Iwata ; Hiroki Segawa ; Tadashi Yamamuro ; Kenji Kuwayama ; Kenji Tsujikawa ; Hiroyuki Inoue

Purpose:

The usefulness of hepatocytes isolated from a liver-humanized mouse (PXB-cells) as a model in vitro system for the prediction of the in vivo metabolism of new drugs of abuse was evaluated.

Methods:

For the drug metabolism study, fentanyl, a powerful synthetic opioid, and acetylfentanyl, an N-acetyl analog of fentanyl, were selected as model drugs. PXB-cells were cultured with the drug for 24-48 h and then the media were collected and analyzed by liquid chromatography/mass spectrometry after deproteinization with acetonitrile.

Results:

The main metabolite formed from fentanyl by PXB-cells was the desphenethylated metabolite (nor-fentanyl), and the other major metabolites formed were 4'-hydroxy-fentanyl, β-hydroxy-fentanyl and (ω-1)-hydroxy-fentanyl. ω-Hydroxy-fentanyl and 4'-hydroxy-3'-methoxy-fentanyl were the minor metabolites. Similar results were obtained for acetylfentanyl. The metabolite profile of fentanyl in PXB-cells was consistent with the in vivo metabolite profile of fentanyl reported previously. Most of the 4'-hydroxy- and 4'-hydroxy-3'-methoxy-metabolites of fentanyl and acetylfentanyl were conjugated in PXB-cells, indicating that PXB-cells had high conjugation enzyme activities. From experiments using human liver microsomes and anti-CYP antibodies, it was revealed that CYP3A4 was involved in the production of nor-fentanyl, β-hydroxy-fentanyl and (ω-1)-hydroxy-fentanyl, while CYP2D6 was partially involved in the production of 4'-hydroxy-fentanyl.

Conclusions:

Our results indicated that PXB-cells have high activities of phase I and phase II drug-metabolizing-enzymes, can be stably supplied, and are easy to use; thus, PXB-cells are highly useful for the prediction of the in vivo metabolism of drugs of abuse.

2013-08-01·Clinical Lymphoma, Myeloma & Leukemia4区 · 医学

Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

4区 · 医学

Article

作者: Wetzler, Meir ; Thomas, Debora A. ; Wang, Eunice S. ; Shepard, Robert ; Ford, Laurie A. ; Heffner, Thompson L. ; Parekh, Samir ; Andreeff, Michael ; O'Brien, Susan ; Kantarjian, Hagop M.

BACKGROUND:

Treatment options for relapsed/refractory ALL in adult patients remain challenging. Annamycin is a highly lipophilic form of the anthracycline doxorubicin with the ability to bypass multidrug resistance mechanisms of cellular drug resistance.

PATIENTS AND METHODS:

We performed a phase I/II multicenter, open-label, study to determine the maximally tolerated dose (MTD) of nanomolecular liposomal annamycin in adult patients with refractory ALL.

RESULTS:

Thirty-one patients were enrolled; the MTD was determined to be 150 mg/m(2)/d for 3 days. Other than tumor lysis syndrome, there were 3 grade 3 mucositis which comprised the MTD determination. There was also 1 case each of grade 3 diarrhea, typhlitis, and nausea. After determining the MTD, a 10-patient phase IIA trial was conducted. Eight of the patients completed 1 cycle of the 3 days of treatment at the MTD. Of these, 5 (62%) had an efficacy signal with complete clearing of circulating peripheral blasts. Three of these subjects also cleared bone marrow blasts with 1 subsequently proceeding onto successful stem cell transplantation.

CONCLUSION:

Single-agent nanomolecular liposomal annamycin appears to be well tolerated, and shows evidence of clinical activity as a single agent in refractory adult ALL.

项与安纳霉素相关的新闻（医药）

2024-03-31

·药明康德

4周体重下降近10斤的小分子减肥药物；疾病发作率降低超90%的单抗… | 一周盘点

▎药明康德内容团队编辑本期看点1. 小分子口服疗法VK2735在治疗肥胖症的1期临床试验中获得了积极结果，接受最高剂量治疗的受试者在28天后体重减少5.3%。2. 用于治疗Dravet综合征的反义寡核苷酸（ASO）疗法STK-001在早期临床试验中的疗效亮眼，用药后3个月时，患者的癫痫发作频率降低了85%。3. 6个月内使用1-2次血浆激肽释放酶单克隆抗体抑制剂STAR-0215在早期临床试验中使遗传性血管性水肿（HAE）患者的每月发作率降低了90%-96%。药明康德内容团队整理VK2735：公布1期临床试验的新数据Viking Therapeutics公司于近期宣布，该公司的口服疗法VK2735在治疗肥胖症的1期临床试验中获得了积极结果。VK2735是胰高血糖素样肽1（GLP-1）和葡萄糖依赖性促胰岛素多肽（GIP）受体的双重激动剂，正在开发用于治疗肥胖等各种代谢性疾病。GIP和GLP-1是调控血糖的天然肠促胰岛素激素。这项为期28天的剂量递增研究结果突显了口服VK2735治疗的积极临床活性。接受VK2735治疗的患者队列显示出剂量依赖性体重减少，与基线相比最高达到5.3%（4.9公斤）。接受VK2735治疗的队列与安慰剂相比也显示平均体重减少，最高可达3.3%。基于这些1期试验结果，该公司计划在今年晚些时候，启动VK2735口服剂型治疗肥胖的2期临床试验。▲口服VK2735剂量依赖性降低受试者体重（图片来源：Viking Therapeutics公司官网）STK-001：公布1/2a期临床试验的新数据Stoke Therapeutics公司公布了其在研ASO疗法STK-001在两项1/2a期试验与两项开放标签扩展（OLE）试验中，治疗Dravet综合征儿童和青少年患者的积极数据。Dravet综合征通常与编码NaV1.1通道α亚基的SCN1A基因发生突变有关。人体中有两个SCN1A基因拷贝，如果其中一个拷贝因为产生突变而无法产生功能性蛋白，会导致NaV1.1蛋白水平下降。STK-001旨在通过与正常SCN1A基因拷贝生成的mRNA前体结合，促进更多能够表达蛋白的成熟mRNA的产生，从而恢复NaV1.1水平，减少癫痫发作和非癫痫合并症的发生。STK-001已被美国FDA和欧洲药品管理局（EMA）授予孤儿药资格，并被美国FDA授予罕见儿科疾病资格，用以治疗Dravet综合征。此次公布的结果显示，STK-001在给药后3个月可显著且持久地降低患者癫痫发作频率达85%，且药物的耐受性良好。此外，12个月时，患者的多种认知和行为测量结果均具有临床意义的改善，包括Vineland适应性行为量表（VINELAND-3）中的多个参数，这些结果支持STK-001具有改变疾病进展的潜力。Stoke公司将与监管机构讨论相关随机对照注册研究计划，以进一步推动STK-001的开发。根据新闻稿，这些数据支持STK-001成为首款具改变疾病进展能力的Dravet综合征药物。STAR-0215：公布1b/2期临床试验的初步数据Astria Therapeutics公司公布了其用于治疗遗传性血管性水肿的血浆激肽释放酶单抗抑制剂STAR-0215的1b/2期临床试验的初步数据。此前公布的1a期临床试验结果显示，STAR-0215具有作为长效血浆激肽释放酶抑制剂的潜力，半衰期长达117天，支持STAR-0215每三个月给药一次或以更低的频率给药。此次公布的结果显示，在6个月内给药1次或2次STAR-0215，可将HAE的每月发病率降低90%-96%，该结果支持每年仅给药2次或4次。此外，使用STAR-0215后，中度或严重HAE发作减少了92%-100%，需要使用急救药物的发作减少了91%-95%。安全性方面，STAR-0215的耐受性非常好，无严重不良事件，无停药现象。▲接受STAR-0215治疗的HAE患者的每月发病率（图片来源：参考资料[3]）ABBV-RGX-314：公布1/2a期临床试验的初步数据REGENXBIO公司公布了其一次性视网膜下注射的基因疗法ABBV-RGX-314用于治疗湿性年龄相关性黄斑变性（AMD）患者的早期安全性和耐受性数据。ABBV-RGX-314以该公司专有的NAV平台开发的腺相关病毒8（AAV8）作为载体，搭载旨在抑制血管内皮生长因子（VEGF）的抗体片段的基因编码。ABBV-RGX-314通过抑制VEGF通路从而抑制新的、渗漏的血管生长及其导致的视网膜积液。此次公布的结果表明，单次注射ABBV-RGX-314的耐受性普遍良好。两年后，大多数患者的视力和视网膜厚度保持稳定或有所改善，只需少量或无需补充注射抗VEGF疗法。REGENXBIO公司还报告了ABBV-RGX-314长期随访研究的其他积极中期数据，结果表明，该疗法的耐受性良好，并显示出长达四年的长期且持久的治疗效果。CAN-3110：公布1b期临床试验的新数据Candel Therapeutics公司公布了其用于治疗复发性高级别胶质瘤（rHGG）的候选溶瘤病毒疗法CAN-3110的1b期临床试验的新数据。CAN-3110是潜在“first-in-class”的单纯疱疹病毒-1（HSV-1）溶瘤免疫疗法，具有溶瘤和免疫激活的双重活性。该疗法使用的病毒经过工程化设计，具有复制能力，其负责病毒复制的基因ICP34.5受Nestin特异性启动子的转录控制。Nestin在神经胶质瘤细胞和其他肿瘤组织中高表达，但不在健康成人的大脑中表达，故通过此设计可避免CAN-3110影响邻近的正常细胞。此前公布的数据显示，接受了单次瘤内注射CAN-3110治疗的rHGG患者的中位总生存期（OS）有所改善，为11.6个月，而此类患者的历史中位OS约为6-9个月。HSV-1血清学阳性是一种预测缓解的指标，并与生存率的提高有关，HSV-1血清学阳性患者的中位OS达到了14个月。此次公布的结果表明，在rHGG患者中重复注射CAN-3110是可行的，而且耐受性良好，未观察到剂量限制性毒性。此外，重复注射CAN-3110有望进一步提高这种在研药物的临床活性。SNK01：公布1期临床试验数据NKGen Biotech公司公布其在研自然杀伤（NK）细胞疗法SNK01用于治疗阿尔茨海默病（AD）的1期临床试验数据。SNK01是一款自体、非基因工程改造的NK细胞产品。它具有增强的细胞毒性和激活性受体的表达。此次公布的试验结果显示，SNK01除了先前披露的对淀粉样蛋白β（Aβ）和神经炎症生物标志物的积极影响外，对晚期阿尔茨海默病患者的认知功能也具有临床疗效。静脉输注的SNK01能够穿过血脑屏障，降低脑脊液（CSF）中的生物标志物水平，包括Aβ42/40、Tau蛋白和α-突触核蛋白。在10名可评估AD患者中，90%患者的ADCOMS评分较基线时有改善或保持稳定。50%患者CSF中的pTau217降低；80%患者的CSF pTau181较基线时稳定/降低；30%患者的血浆pTau217降低；40%患者的血浆pTau181降低，这些效果一直延续到第22周。安全性方面，未观察到治疗相关不良事件。Annamycin：公布1b/2期临床试验数据Moleculin Biotech公司公布了其下一代蒽环类小分子疗法annamycin联用阿糖胞苷（AnnAraC）用于治疗复发/难治性急性髓系白血病（AML）患者的1b/2期临床试验的积极结果。在动物模型中，annamycin已被证明在肺部积累的含量为阿霉素的30倍，在多项早期人体临床试验中未显示出在蒽环类药物中常见的心脏毒性。此次公布的数据显示，AnnAraC治疗AML患者的复合完全缓解（CRc）率达到了60%，完全缓解（CR）率为50%。新闻稿指出，AnnAraC有望使接受二线治疗的AML患者的CR率比接受现有二线疗法的AML患者提高一倍以上。此外，在多项研究中，所有82名接受annamycin治疗的受试者在研究期间均未出现心脏毒性症状，毒性低于传统的强化疗法。BEN-8744：公布1a期临床试验数据BenevolentAI公司公布了其在健康受试者中开展的BEN-8744的1a期临床研究的积极安全性数据。BEN-8744是一种口服、外周限制性PDE10抑制剂，目前正被开发为中度至重度溃疡性结肠炎（UC）患者的潜在“first-in-class”治疗药物。PDE10是一种双重磷酸二酯酶，可降低细胞内信号分子cAMP和cGMP的水平。BEN-8744旨在抑制PDE10以恢复cAMP和cGMP的水平，有望通过改善屏障的完整性直接起到抗炎和潜在的疾病调节作用。该1a期研究达到了主要目标。BEN-8744的安全性和耐受性良好，任何剂量组均未报告严重不良事件（SAE）。药代动力学特征表明，每日两次给药BEN-8744能达到所需的PDE10靶点覆盖率，从而在UC患者的后续临床研究中产生潜在的治疗效果。该公司的新闻稿指出，以PDE10为靶点的BEN-8744与现有的标准治疗方法相比具有显著的差异化潜力。VRON-0200：公布1b期临床试验数据Virion Therapeutics公司公布了其新型、潜在“first-in-class”的检查点修饰免疫疗法VRON-0200用于功能性治愈慢性乙型肝炎病毒（HBV）感染患者的1b期临床试验的安全性数据。结果显示，前10名接受治疗的慢性HBV感染患者对VRON-0200的耐受性良好，没有报告重大不良事件，也没有报告实验室检查、心电图（ECG）或生命体征等方面的临床相关异常。大家都在看作为药明康德旗下专注于细胞和基因疗法的CTDMO，药明生基致力于加速和变革基因和细胞治疗及其他高端治疗的开发、测试、生产和商业化。药明生基能够助力全球客户将更多创新疗法早日推向市场，造福病患。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料（可上下滑动查看）[1] BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers. Retrieved March 25, from https://www.businesswire.com/news/home/20240324322513/en[2] Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial. Retrieved March 26, from https://www.prnewswire.com/news-releases/moleculin-announces-positive-interim-data-in-annamycin-mb-106-phase-1b2-aml-trial-302097561.html[3] Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE. Retrieved March 26, from https://www.businesswire.com/news/home/20240325940590/en/[4] Aptamer Sciences Inc. Files IND Application for Innovative Liver Cancer Treatment AST-201: A Promising Approach to Address Under Medical Needs. Retrieved March 26, from https://www.prnewswire.com/news-releases/aptamer-sciences-inc-files-ind-application-for-innovative-liver-cancer-treatment-ast-201-a-promising-approach-to-address-under-medical-needs-302098802.html[5] NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference. Retrieved March 26, from https://www.globenewswire.com/news-release/2024/03/25/2851989/0/en/NKGen-Biotech-Presents-Additional-Phase-1-Clinical-Trial-Data-in-Alzheimer-s-Disease-at-the-Tau2024-Global-Conference.html[6] Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases. Retrieved March 26, from https://www.globenewswire.com/news-release/2024/03/25/2851495/0/en/Apogee-Therapeutics-Announces-First-Participants-Dosed-in-Phase-1-Trial-of-APG808-its-Novel-Half-life-Extended-IL-4R%CE%B1-Antibody-for-the-Treatment-of-Chronic-Obstructive-Pulmonary-Di.html[7] Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist. Retrieved March 26, from https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-first-patient-dosed-phase-1[8] Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome. Retrieved March 26, from https://www.businesswire.com/news/home/20240325745654/en[9] Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure. Retrieved March 26, from https://www.businesswire.com/news/home/20240325487405/en[9] Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate. Retrieved March 26, from https://valneva.com/press-release/valneva-initiates-phase-1-trial-of-second-generation-zika-vaccine-candidate/[10] Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5. Retrieved March 26, from https://opusgtx.com/companynews/opus-genetics-announces-completion-of-dosing-in-first-cohort-of-phase-1-2-trial-of-gene-therapy-opgx-lca5-in-patients-with-rare-inherited-retinal-disease-lca5/[11] CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity. Retrieved March 26, from https://www.businesswire.com/news/home/20240326703050/en[12] Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735. Retrieved March 26, 2024, from https://www.prnewswire.com/news-releases/viking-therapeutics-announces-results-from-phase-1-clinical-trial-of-oral-tablet-formulation-of-dual-glp-1gip-receptor-agonist-vk2735-302098869.html[13] Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations. Retrieved March 28, 2024, from https://ir.immuneering.com/news-releases/news-release-details/immuneering-announces-first-patient-dosed-its-phase-12a-trial[14] Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors. Retrieved March 28, 2024, from https://www.businesswire.com/news/home/20240327705577/en[15] Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat. Retrieved March 28, 2024, from https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-announces-completion-phase-1-hepatic[16] Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting. Retrieved March 28, 2024, from https://www.prnewswire.com/news-releases/promising-first-in-human-phase-1b-clinical-study-data-from-vron-0200-a-novel-first-in-class-checkpoint-modifier-immunotherapy-for-chronic-hepatitis-b-virus-functional-cure-presented-as-late-breaker-at-2024-apasl-global-liver-me-302100640.html[17] Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma. Retrieved March 28, 2024, from https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-oral-presentation-during-5th[18] Nested Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NST-628, a Novel Pan-RAF/MEK Molecular Glue. Retrieved March 28, 2024, from https://www.prnewswire.com/news-releases/nested-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-nst-628-a-novel-pan-rafmek-molecular-glue-302101827.html[19] REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD. Retrieved March 28, 2024, from https://www.prnewswire.com/news-releases/regenxbio-announces-lancet-publication-of-phase-iiia-study-evaluating-abbv-rgx-314-as-a-one-time-gene-therapy-for-wet-amd-302102175.html[20] Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults. Retrieved March 28, 2024, from https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-effects-of-nbi-1065890-a-second-generation-vmat2-inhibitor-in-healthy-adults-302101715.html[21] Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial. Retrieved March 28, 2024, from https://www.businesswire.com/news/home/20240328939779/en[22] MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR ML-007/PAC, UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER'S DISEASE PSYCHOSIS. Retrieved March 28, 2024, from https://www.prnewswire.com/news-releases/maplight-therapeutics-announces-initiation-of-phase-1-clinical-trial-for-ml-007pac-under-development-for-schizophrenia-and-alzheimers-disease-psychosis-302102849.html免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床2期临床结果寡核苷酸临床1期孤儿药

2024-03-28

·PRNewswire

Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference

Live webcast on Thursday, April 4th at 4:10 PM ET HOUSTON, March 28, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Walter Klemp, President and Chief Executive Officer of Moleculin will present at the MedInvest Biotech & Pharma Investor Conference behind held in New York City, NY on Thursday, April 4, 2024 at 4:10 PM ET. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website. A live webcast of the event will be available on the Events page in the Investors section of the Company's website (moleculin.com). About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. For more information about the Company, please visit and connect on Twitter, LinkedIn and Facebook. Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 [email protected] SOURCE Moleculin Biotech, Inc.

临床2期免疫疗法

2024-03-27

·PRNewswire

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity

Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Thursday, March 28th at 12:00 PM ET HOUSTON, March 27, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will present at the Virtual Investor Lunch Break: The Moleculin Opportunity event on Thursday, March 28, 2024 at 12:00 PM ET. As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, will provide a corporate overview, business outlook, and discuss the Moleculin opportunity. A live video webcast of the event will be available on the Events page under the Investors section of the Company's website (moleculin.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days. About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. For more information about the Company, please visit and connect on Twitter, LinkedIn and Facebook. Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 [email protected] SOURCE Moleculin Biotech, Inc.

临床2期

100 项与安纳霉素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	安纳霉素	-	DB06420

研发状态

适应症	最高研发状态	国家/地区	公司
急性髓性白血病	临床2期	意大利更多	Moleculin Biotech, Inc. 更多
软组织肉瘤	临床2期	美国更多	Moleculin Biotech, Inc. 更多
肉瘤	临床2期	美国更多	Moleculin Biotech, Inc. 更多
成人急性髓性白血病	临床2期	波兰更多	Moleculin Biotech, Inc. 更多
复发性急性淋巴细胞白血病	临床1期	美国更多	Callisto Pharmaceuticals, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04887298 (AACR2022)	临床1/2期	结肠转移性腺癌	-	L-Annamycin	(壓觸夢壓鬱網積顧積鬱) = 壓壓憲壓積觸鹽鏇餘繭廠憲鬱範網糧憲鏇鑰襯 (獵鏇觸齋築窪鹽積廠遞 )	-	2022-06-15
				Vehicle	(壓觸夢壓鬱網積顧積鬱) = 遞鑰醖簾選蓋壓製鹹衊廠憲鬱範網糧憲鏇鑰襯 (獵鏇觸齋築窪鹽積廠遞 )
NCT04887298 (MB107, Biospace) 人工标引	临床1/2期	肉瘤	33	Annamycin	(簾齋餘壓襯壓獵廠選網) = 窪艱廠鹽蓋齋壓窪鹽廠簾蓋簾築糧膚蓋網觸夢 (壓鹽餘襯鑰鹽淵膚網顧 )	积极	2023-11-06
				Annamycin 330 mg/m2	(網鑰齋淵網簾醖淵窪艱) = 積鑰網鏇築蓋積觸蓋簾顧鑰繭壓廠築齋窪衊遞 (壓淵襯鹹範鹹壓獵鏇構 )
NCT05319587 (MB-106 AML, Biospace) 人工标引	临床2期	急性髓性白血病	8	Annamycin 240 mg/m2 (Study MB-105)	顧醖壓糧壓獵網簾願廠(觸遞蓋廠淵網窪築鹹獵) = 壓鹽顧構積網簾廠膚衊鹹鬱構醖製簾餘醖蓋範 (糧餘獵蓋鑰衊齋顧膚繭 ) 更多	积极	2023-11-13
				Ara-C + Annamycin (Study MB-106 Combination Therapy – Phase 1B)	顧醖壓糧壓獵網簾願廠(觸遞蓋廠淵網窪築鹹獵) = 鑰鹹憲餘顧積觸鬱襯餘鹹鬱構醖製簾餘醖蓋範 (糧餘獵蓋鑰衊齋顧膚繭 ) 更多
NCT04887298 (PRNewswire) 人工标引	临床1/2期	继发性肺恶性肿瘤	-	Annamycin	(襯鏇壓壓膚鑰淵觸鹽獵) = demonstrate no evidence of cardiotoxicity to date 憲鬱淵蓋網醖襯積襯選 (鬱築齋膚顧鑰網範觸蓋 )	积极	2023-09-18
NCT05319587 (PRNewswire) 人工标引	临床1/2期	急性髓性白血病一线	-	Annamycin+Cytarabine	(窪齋糧選鹹鑰遞範鹹齋) = 遞餘選憲齋獵醖壓獵窪鏇醖壓壓繭積憲憲艱選 (範壓範醖構築簾壓膚廠 ) 更多	积极	2024-01-24
				AnnamycinAnnamycinAnnamycin+CytarabineCytarabineCytarabine (dosed with Annamycin)	(窪齋糧選鹹鑰遞範鹹齋) = 餘衊構築糧壓獵鏇鹽構鏇醖壓壓繭積憲憲艱選 (範壓範醖構築簾壓膚廠 ) 更多
ASCO2009	临床1期	难治性急性淋巴细胞白血病二线	-	nanomolecular liposomal annamycin	(構廠鹽願繭觸顧鏇窪糧) = 齋淵醖選艱積網顧廠遞淵鬱淵壓製餘鏇糧蓋製 (顧窪簾艱願鏇鏇壓壓構 ) 更多	-	2009-05-20
MB-107 STS (Biospace) 人工标引	临床2期	软组织肉瘤	32	Annamycin	(製衊窪觸廠憲獵醖鹹構) = 膚鹽醖窪構餘鹽簾齋齋顧繭網衊鑰窪鑰鏇廠艱 (膚遞窪醖鬱衊構糧艱廠 ) 更多	积极	2023-11-13
				Annamycin (Phase 1B)	(製衊窪觸廠憲獵醖鹹構) = 獵鏇艱糧願網鑰觸繭觸顧繭網衊鑰窪鑰鏇廠艱 (膚遞窪醖鬱衊構糧艱廠 ) 更多